Abivertinib

DB15327InvestigationalSmall molecule

Abivertinib is a tyrosine kinase inhibitor targeted against mutant forms of both human epidermal growth factor receptor (EGFR) and Bruton's tyrosine kinase (BTK). It has been investigated for use in... It has been investigated for use in the treatment of non-small cell lung cancer (NSCLC) and B-cell malignancies.

Mechanism: Pharmacologically active on Tyrosine-protein kinase BTK and Epidermal growth factor receptor
Curator reviewed
Formula / weight: C₂₆H₂₆FN₇O₂ · 487.539 g/mol (avg)
Code names: A610 · AC-0010 · ACEA100610 · EX-ACEA0010

Resolves to

Compound

UNIICER0OPG92LCAS1557267-42-1ChEMBLCHEMBL4297865

Structure

InChIKeyUOFYSRZSLXWIQB-UHFFFAOYSA-NSMILESCN1CCN(CC1)C1=C(F)C=C(NC2=NC(OC3=CC=CC(NC(=O)C=C)=C3)=C3C=CNC3=N2)C=C1

Targets

Q06187BTKP00533EGFR

What you can answer from here — as of September 13, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

10Clinical trialsPhase, status and sponsor resolved per trial

16+ReferencesStructured and connected to the statements they support

Which drugs share a target with Abivertinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account